USA - NASDAQ:IBRX - US45256X1037 - Common Stock
ChartMill assigns a Buy % Consensus number of 85% to IBRX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-26 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-20 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2025-05-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-15 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-31 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-06 | HC Wainwright & Co. | Initiate | Buy |
| 2025-03-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-30 | D. Boral Capital | Maintains | Buy -> Buy |
11 analysts have analysed IBRX and the average price target is 10.4 USD. This implies a price increase of 391.91% is expected in the next year compared to the current price of 2.115.
The consensus rating for IMMUNITYBIO INC (IBRX) is 85.4545 / 100 . This indicates that analysts generally have a positive outlook on the stock.